DAY ONE BIOPHARMACEUTICALS I's ticker is DAWN and the CUSIP is 23954D109. A total of 129 filers reported holding DAY ONE BIOPHARMACEUTICALS I in Q3 2023. The put-call ratio across all filers is 2.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $30,571,453 | +0.5% | 2,491,561 | -2.2% | 26.81% | +24.4% |
| Q2 2023 | $30,427,932 | -10.7% | 2,548,403 | 0.0% | 21.55% | -12.1% |
| Q1 2023 | $34,072,148 | -37.9% | 2,548,403 | 0.0% | 24.51% | -43.1% |
| Q4 2022 | $54,841,633 | -60.7% | 2,548,403 | -63.4% | 43.06% | -23.5% |
| Q3 2022 | $139,495,000 | -19.4% | 6,964,301 | -27.9% | 56.26% | -8.7% |
| Q2 2022 | $172,979,000 | +80.4% | 9,663,645 | 0.0% | 61.60% | +54.3% |
| Q1 2022 | $95,863,000 | -41.1% | 9,663,645 | 0.0% | 39.92% | -4.8% |
| Q4 2021 | $162,832,000 | – | 9,663,645 | – | 41.94% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners XI LLC | 2,491,561 | $30,571,453 | 26.81% |
| Atlas Venture Life Science Advisors, LLC | 7,608,394 | $93,354,994 | 14.46% |
| DAFNA Capital Management LLC | 586,463 | $7,195,901 | 2.24% |
| Nicholas Investment Partners, LP | 2,188,654 | $26,854,785 | 2.01% |
| RA Capital Management | 7,809,852 | $95,826,884 | 1.89% |
| BRAIDWELL LP | 3,715,573 | $45,590,081 | 1.44% |
| PFM Health Sciences, LP | 2,224,598 | $27,295,817 | 1.29% |
| SPHERA FUNDS MANAGEMENT LTD. | 530,000 | $6,503,100 | 1.18% |
| COMMODORE CAPITAL LP | 739,661 | $9,075,640 | 1.06% |
| Parkman Healthcare Partners LLC | 466,408 | $5,722,826 | 1.05% |